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ABSTRACT
Introduction Capsular group B Neisseria meningitidis 
(MenB) is the most common cause of invasive 
meningococcal disease (IMD) in many parts of the world. 
A MenB vaccine directed against the polysaccharide 
capsule remains elusive due to poor immunogenicity and 
safety concerns. The vaccines licensed for the prevention 
of MenB disease, 4CMenB (Bexsero) and MenB- fHbp 
(Trumenba), are serogroup B ‘substitute’ vaccines, 
comprised of subcapsular proteins and are designed to 
provide protection against most MenB disease- causing 
strains. In many high- income countries, such as the 
UK, adolescents are at increased risk of IMD and have 
the highest rates of meningococcal carriage. Beginning 
in the late 1990s, immunisation of this age group with 
the meningococcal group C conjugate vaccine reduced 
asymptomatic carriage and disrupted transmission of 
this organism, resulting in lower group C IMD incidence 
across all age groups. Whether vaccinating teenagers 
with the novel ‘MenB’ protein- based vaccines will prevent 
acquisition or reduce duration of carriage and generate 
herd protection was unknown at the time of vaccine 
introduction and could not be inferred from the effects of 
the conjugate vaccines. 4CMenB and MenB- fHbp may also 
impact on non- MenB disease- causing capsular groups as 
well as commensal Neisseria spp. This study will evaluate 
the impact of vaccination with 4CMenB or MenB- fHbp 
on oropharyngeal carriage of pathogenic meningococci 
in teenagers, and consequently the potential for these 
vaccines to provide broad community protection against 
MenB disease.
Methods and analysis The ‘Be on the TEAM’ (Teenagers 
Against Meningitis) Study is a pragmatic, partially 
randomised controlled trial of 24 000 students aged 
16–19 years in their penultimate year of secondary school 
across the UK with regional allocation to a 0+6 month 
schedule of 4CMenB or MenB- fHbp or to a control 
group. Culture- confirmed oropharyngeal carriage will be 
assessed at baseline and at 12 months, following which 
the control group will be eligible for 4CMenB vaccination. 
The primary outcome is the carriage prevalence of 
potentially pathogenic meningococci (defined as those 
with genogroups B, C, W, Y or X), in each vaccine group 
compared separately to the control group at 12 months 
post- enrolment, that is, 12 months after the first vaccine 
dose and 6 months after the second vaccine dose. 
Secondary outcomes include impact on carriage of: 
genogroup B meningococci; hyperinvasive meningococci; 
all meningococci; those meningococci expressing 
vaccine antigens and; other Neisseria spp. A sample size 
of 8000 in each arm will provide 80% power to detect 
a 30% reduction in meningococcal carriage, assuming 
genogroup B, C, W, Y or X meningococci carriage of 3.43%, 
Strengths and limitations of this study
 ► The scale of this carriage study will compensate for 
the known variation in carriage rates that can occur 
even when consistent methodology is used across 
multiple sites. The wide geographical distribution of 
study sites increases applicability to other settings.
 ► Regional allocation of schools to the same study 
group may increase the power to detect population 
effects in discrete social networks.
 ► The duration of post- immunisation follow- up (6 
months) and a single post- immunisation sampling 
point limits the potential to identify a longer- term 
or more short- lived reduction in carriage, however, 
the mobility of school- leavers renders longer- term 
follow- up during the highest period of acquisition 
infeasible in this study.
 ► This study will inform modelling estimates of poten-
tial community- wide impact of adolescent immuni-
sation with either 4CMenB or MenB- fHbp, which are 
dependent on whether these vaccines induce herd 
protection.
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a design effect of 1.5, a retention rate of 80% and a significance level of 
0.05. Study results will be available in 2021 and will inform the UK and 
international immunisation policy and future vaccine development.
Ethics and dissemination This study is approved by the National Health 
Service South Central Research Ethics Committee (18/SC/0055); the UK 
Health Research Authority (IRAS ID 239091) and the UK Medicines and 
Healthcare products Regulatory Agency. Publications arising from this 
study will be submitted to peer- reviewed journals. Study results will be 
disseminated in public forums, online, presented at local and international 
conferences and made available to the participating schools.
Trial registration numbers ISRCTN75858406; Pre- results, EudraCT 
2017-004609-42.
INTRODUCTION
Background and rationale
Capsular group B Neisseria meningitidis (MenB) accounts 
for most cases of invasive meningococcal disease (IMD) 
in the UK, Europe, North America, Australia, New 
Zealand and many countries in Latin America.1–3 Most 
IMD cases occur in infants and young children, with a 
smaller peak in incidence in late adolescence. Despite 
advances in recognition and management, the global 
case fatality rate remains 9%, with substantial sequelae in 
many survivors.1 While conjugate vaccines that target the 
polysaccharide capsule of groups A, C, W and Y menin-
gococci are highly effective, a capsule- based vaccine for 
MenB remains elusive due to poor immunogenicity and 
potential autoimmunity resulting from homology with 
surface glycoproteins on human embryonic neural cells.4 
Consequently the vaccines licensed for the prevention of 
IMD due to MenB, 4CMenB (Bexsero, GSK) and MenB- 
fHbp (Trumenba, Pfizer), target subcapsular proteins. 
These proteins are highly diverse and have variable 
density of surface expression. Thus, adequate breadth of 
coverage relies on a multi- component strategy and poten-
tial to generate cross- protective vaccine- induced anti-
bodies. The 4CMenB vaccine contains factor H- binding 
protein (fHbp) from subfamily B/variant 1 fused with 
the accessory protein GNA2091; Neisserial heparin- 
binding antigen, Neisserial adhesin A fused with the 
accessory protein GNA1030 and an outer- membrane 
vesicle NZ98/254 (PorA 1.4). MenB- fHbp contains two 
self- lipidated alleles of fHbp, one each from subfamily A/
variant 3 and subfamily B/variant 1. 4CMenB and MenB- 
fHbp were licensed based on safety and immunogenicity 
data determined by human serum bactericidal antibody 
activity as an established correlate of protection.5 6
In September 2015, the UK introduced a routine 
4CMenB infant immunisation programme, in which 
all infants born after the 1st of May 2015 are eligible to 
receive a 2+1 schedule of 4CMenB at 2, 4 and 12 months 
of age. Ten months after introduction, the effectiveness 
of the 2- month and 4- month doses against all MenB 
IMD was estimated at 83% with very broad uncertainty 
(95% CI 24.1–95.2), a result consistent with the estimated 
breadth of coverage from immunogenicity studies.3 At 
3 years, expected cases of MenB IMD in vaccine- eligible 
children reduced by 75%.7 Vaccine effectiveness of the 
2+1 schedule was 59.1% (95% CI 31.1–97.2) against all 
MenB IMD and 71.2% against vaccine preventable MenB 
strains. There are no other vaccine effectiveness studies 
for either 4CMenB or MenB- fHbp.
Herd protection was not observed or expected from 
the UK MenB infant programme because carriage is 
very rare in infants as compared with the peak carriage 
rates that occur in late adolescence and early adulthood.8 
The potential for indirect protection to enhance vaccine 
impact and cost- effectiveness is exemplified by the menin-
gococcal group C conjugate (MCC) vaccine campaign 
that included children, adolescents and young adults. A 
reduction in carriage in this targeted population dramat-
ically reduced IMD caused by serogroup C meningo-
coccus (MenC) in all age groups in the UK.9 Maintaining 
this reduction in carriage and therefore MenC IMD in 
the UK is the primary rationale for an adolescent booster 
dose of a MenC containing vaccine in early adolescence 
following infant priming with a single MCC dose given at 
12 months of age.
Based on modelling estimates, an infant- only MenB 
immunisation programme may prevent 26.3% of all- age 
IMD in the first 5 years after introduction.10 If MenB 
vaccines could reduce meningococcal carriage by 30% 
and therefore disrupt transmission, a combined infant 
and adolescent immunisation programme could reduce 
all- age annual cases by 48.8% at 10 years and 59.7% at 
20 years after introduction, enhancing impact and cost- 
effectiveness.10 The impact of 4CMenB immunisation on 
carriage has been studied in two randomised controlled 
trials (RCTs) to date. The ‘B Part of It’ cluster- RCT assessed 
the impact of immunisation with 4CMenB on carriage in 
24 269 secondary school students in Australia.11 There was 
no impact on carriage of pathogenic genogroups A, B, C, 
W, Y or X at 12 months following immunisation. In the 
UK, 2954 university students were randomised to receive 
4CMenB, MenACWY- CRM, or to an active control.12 
This study showed no effect on the primary outcome of 
carriage prevalence 1 month after a two- dose schedule of 
4CMenB. Using a composite end point of carriage at any 
timepoint 3–12 months following immunisation, admin-
istration of 4CMenB reduced carriage of any meningo-
coccus by 18.2% (95% CI 3.4–30.8) and meningococcus 
groups B, C, W and Y combined by 26.6% (95% CI 
10.5–39.9). This reduction was primarily due to a fall in 
carriage of meningococci of capsular groups C, W and Y, 
with a non- significant change in capsular group B menin-
gococcal carriage. Only a minority of students at any insti-
tution received the vaccine, which reduced the potential 
impact of herd protection in the cohort. Studies assessing 
MenB- fHbp carriage impact are limited to observational 
reports of several small MenB outbreaks in US universi-
ties,13 where a number of interventions including mass- 
immunisation campaigns halted new cases, however these 
studies were not specifically designed or powered to show 
an impact of MenB- fHbp vaccine on carriage.
4CMenB and MenB- fHbp may elicit immune responses 
against non- MenB meningococci and, for 4CMenB, N. 
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gonorrhoeae.14 15 Vaccine antigens may also be present in 
commensal Neisseria spp. resident in the oropharynx.15 16 
While cross- protection against meningococci expressing 
other disease- associated capsular groups is desirable, a 
broader impact on colonising strains of N. meningitidis or 
potentially protective non- invasive organisms, such as N. 
lactamica, requires surveillance. Unencapsulated menin-
gococci, which are generally non- pathogenic, may have 
greater surface exposure of vaccine antigens and there-
fore be more vulnerable to mucosal clearance than the 
potentially invasive capsule- expressing meningococci. 
Natural exposure to these bacteria throughout childhood 
contributes to the development of immunity against 
hyperinvasive strains.17 It is not known whether vaccines 
that induce immunity to these Neisseria spp. may facilitate 
an unintended niche for pathogenic meningococci.
METHODS
Study design
The ‘Be on the TEAM’ (Teenagers Against Menin-
gitis) Study is a pragmatic, partially randomised cluster 
controlled trial that will evaluate the carriage prevalence 
of pathogenic meningococci in adolescents vaccinated 
with either 4CMenB or MenB- fHbp, compared with 
a control group. Participants aged 16–19 years will be 
enrolled in 16 regions across the UK, with each region 
allocated to: (1) vaccination at 0 and 6 months with 
4CMenB (‘4CMenB Group’); (2) vaccination at 0 and 6 
months with MenB- fHbp (‘MenB- fHbp Group’) or (3) 
an unvaccinated Control Group who will be eligible for 
deferred vaccination with 4CMenB. Oropharyngeal swab 
samples (OPSs) will be taken at baseline and at 12 months.
Primary Objective
 ► To determine the carriage prevalence of culture- 
confirmed N. meningitidis genogroup B, C, W, Y, X (ie, 
those meningococci possessing genes encoding the 
capsular polysaccharides corresponding to the respec-
tive serogroups) at 12 months after baseline vaccina-
tion (6 months following the second vaccine dose) in 
the 4CMenB and MenB- fHbp Groups compared with 
the unvaccinated Control Group. The study will not 
directly compare the 4CMenB Group with the MenB- 
fHbp Group.
Secondary Objectives
To determine whether vaccination with either 4CMenB 
or MenB- fHbp affects the carriage prevalence of:
 ► Genogroup B meningococci.
 ► Meningococci of other genogroups and capsule null 
meningococci.
 ► Strains belonging to hyperinvasive meningococcal 
lineages.
 ► All meningococcal strains.
 ► Meningococci expressing antigens contained in 
MenB- fHbp or 4CMenB.
 ► Other Neisseria spp.
A further secondary objective will be to determine any 
difference in rates of new acquisition of carriage between 
groups as defined in the primary and secondary objec-
tives above.
As a stand- alone exploratory objective, this study will 
also permit an assessment of the impact of the UK adoles-
cent quadrivalent MenACWY vaccination programme on 
carriage.18 This campaign was introduced in 2015 due to 
a rise in capsular group W meningococcal disease and has 
high coverage in the school population of prospective 
participants in this study. ‘UKMenCar4’, an adolescent 
carriage study across the same study network in 2014–
2015 will act as the pre- intervention study.19 20 The post- 
intervention carriage prevalence will be determined by 
the baseline carriage samples from the Be on the TEAM 
Study.
Study setting
This is a multi- centre, school- based study in 16 regions 
across the UK (figure 1). Students will be aged 16–19 
years at time of enrolment, attending school or college 
year 12 (in England and Wales) or S5 (in Scotland), or 
Figure 1 Study sites and vaccine group allocation
4 Carr J, et al. BMJ Open 2020;10:e037358. doi:10.1136/bmjopen-2020-037358
Open access 
their equivalent. This will include both government 
(local authority) and independent schools, sixth form 
colleges, single sex or coeducation schools, boarding or 
day schools. Study visits will be conducted in schools, 
although follow- up visits may occur in a community 
setting if participants have left school.
Sample size
The sample size of 24 000 participants (8000 in each 
arm) is based on an estimated carriage rate 3.43% for 
genogroup B, C, W, Y or X in the Control Group at the 
12- month swab. When assuming a retention rate of 80% 
and a design effect of 1.5, this sample size will provide 
80% power to detect a 30% reduction of these geno-
groups combined, at a significance level of 0.05.
This anticipated carriage rate is based on results from 
the UKMenCar4 Study, which determined a carriage prev-
alence of 1.65% for genogroup B meningococcus, 2.3% 
for hyperinvasive meningococci and a combined preva-
lence of 4.2% for genogroup B, C, W, Y and X menin-
gococci.19 The figure of 3.43% accounts for a potential 
50% reduction in carriage of capsular groups W and 
Y due to the UK quadrivalent MenACWY vaccination 
programme; this figure is necessarily an estimate as there 
are limited data on the impact of the universal adoles-
cent quadrivalent ACWY vaccine programme on carriage. 
A previous study in UK university students showed that 
immunisation with MenACWY- CRM reduced carriage 
of genogroup C, W or Y meningococci by 27.1% (95% 
CIs 6.9–42.9) and serogroup C, W or Y by 36.2% (95% 
CIs 15.6–51.7).12 A further UK university carriage cohort 
study suggested that the quadrivalent MenACWY vaccine 
exerts differential effects on capsular groups and did not 
prevent expansion of meningococci belonging to the 
hyperinvasive genogroup W clonal complex 11, although 
this was based on cross- sectional surveys rather than a 
longitudinal design.21
Study timeline
In order to meet recruitment targets and maximise the 
interval between immunisation and the final OPS within 
the structure of the school exam year, the study will recruit 
across 4 ‘waves’ over 20 months: wave 1 March–May 2018; 
wave 2 September–November 2018; wave 3 March–May 
2019; wave 4 September–November 2019 (figure 2). 
The academic teaching year runs from September until 
April or May, depending on local jurisdictions. Recruit-
ment will be balanced between study groups for each of 
the ‘Spring’ (March–May) and ‘Autumn’ (September–
November) recruiting periods in view of expected 
seasonal variation in carriage. Completion of the final 
post- vaccination pharyngeal swab collection is expected 
in early 2021.
Eligibility criteria
Participants will be healthy adolescents aged 16–19 years 
old at time of enrolment, in their penultimate year of 
participating secondary school or sixth form colleges, who 
intend to return for a further year of school. Students will 
be eligible for enrolment if they are willing and able to 
provide informed consent and meet the additional inclu-
sion criteria:
 ► Willing to comply with all study requirements.
 ► Consent for storage of oropharyngeal swabs and any 
bacterial isolates for future research.
Figure 2 Study timeline by recruitment wave and year 12/S5 cohort (penultimate year of secondary school) at the time of 
enrolment. Vaccine groups receive either MenB- fHbp or 4CMenB at 0+6 months. See figure 3 for visit window ranges.
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 ► Willing to allow their general practitioner to be 
contacted to confirm vaccination status or medical 
history.
Participants will be ineligible to participate if they have 
received a course of either 4CMenB or MenB- fHbp in 
the past (by documentation or self- report). Furthermore, 
participants in the 4CMenB Group or MenB- fHbp Group 
will be ineligible if they meet any of the following criteria:
1. History of anaphylaxis to any component of 4CMenB 
or MenB- fHbp (For 4CMenB only, this includes allergy 
to latex).
2. Any other significant disease or disorder, which in the 
opinion of the investigator may: put the participants 
at risk because of participation in the trial, influence 
the result of the trial or affect the participant’s ability 
to participate. Specific examples include haemophilia 
or medically diagnosed bleeding disorder, or receipt 
of anticoagulant medication, that prohibits the use of 
intramuscular injections.
3. Known or suspected pregnancy.
Participants in the Control Group that fail any of the 
specific exclusion criteria 1, 2 or 3 will be eligible to 
participate in the assessment of carriage, but will not be 
able to receive the 4CMenB vaccine after the final OPS. 
Ineligibility arising during the trial due to criteria 1, 2 or 
3 in the 4CMenB Group or MenB- fHbp Group will allow 
inclusion for assessment of carriage at the study endpoint 
but will exclude a participant from vaccination.
STUDY PROCEDURES
Recruitment
Recruitment will occur in participating schools; indi-
vidual participants will not be directly recruited by the 
study teams outside of the school setting. Social media 
and the study website ( www. beontheteam. uk) will be used 
for study information and awareness, but these platforms 
will not be used for recruitment. Participants will receive 
information through a school assembly about meningo-
coccal disease and the study rationale and design. Subse-
quently, they will receive a written participant information 
sheet.
Informed consent
All participants will be aged 16 years or over, and are 
therefore self- consenting as per the National Institute of 
Health Research guidelines.22 However, parents/guard-
ians will be provided with information about the study 
via school communication platforms as well as directly by 
prospective participants. Consent will be taken by clinical 
staff (registered doctor or nurse) or non- clinical staff who 
have had appropriate experience and training. Where 
interested participants have vulnerabilities that may 
impair their capacity to provide informed consent, addi-
tional input or support from the individual’s parents/
guardians will be sought. If there is ongoing doubt about 
an individual’s ability to provide informed consent, then 
they will not be enrolled in the study.
Randomisation, allocation and blinding
This is an open- label partially randomised study, with 
group allocation by study site. All schools within the 
geographical coverage area of each study site will be allo-
cated to the same study arm, both for logistical reasons and 
because geographical allocation may increase the poten-
tial to detect any impact on herd protection. As a post- 
licensure study, blinded administration and/or placebo 
will not impact on the outcome of carriage prevalence 
and would introduce unnecessary cost and complexity to 
a trial of this scale. The allocation of initial sites was deter-
mined prior to the start of the study (figure 1). A capacity 
assessment stratified sites to either the control arm or 
immunisation sites depending on existing site expertise 
and the requirements to maintain equal numbers in each 
study arm. The immunisation sites were randomised to 
either the MenB- fHbp Group or the 4CMenB Group. 
Additional sites may be added during the study and will 
be pragmatically allocated to a study group to ensure 
balanced recruitment.
Interventions
All participants will be required to attend three study visits 
at their school (figure 3). Following informed consent, 
a baseline OPS will be taken by study staff using a stan-
dardised method of collection. A flocked swab will be used 
to sweep from one tonsil across the posterior pharynx 
to the contralateral tonsil. Participants in all groups will 
complete a brief questionnaire collecting demographic 
data and risk factors for meningococcal carriage such as 
smoking and antimicrobial use (see online supplemental 
file).23 The questionnaire is compatible with previous 
large- scale UK meningococcal carriage studies conducted 
in 1999, 2000, 2001 and 2014–2015, and the B Part of It 
Australian Study, which will allow an assessment of risk 
factors over time.11 19 24 25 The 4CMenB and MenB- fHbp 
groups will both receive a two- dose vaccine schedule at 0 
and 6 months and all groups will have a second OPS taken 
at 12 months following enrolment. The Control Group 
will be offered a two- dose schedule of 4CMenB vaccina-
tion after their second OPS. Individual swab results will 
not be given to participants, in accordance with previous 
meningococcal carriage studies, however participants will 
be contacted confidentially if N. gonorrhoeae is detected.
Patient and public involvement
This study will provide a unique opportunity to engage 
adolescents on an unprecedented scale to: (1) increase 
awareness of meningococcal disease; (2) highlight 
the importance of immunisation and (3) stimulate an 
interest in involvement in impact- driven research that 
potentially benefits the broader community. All year 
12 (or equivalent) students at participating schools will 
attend assemblies, often involving meningitis survivors 
and disease- prevention advocates. These ‘meningitis 
ambassadors’ will discuss their personal experience of 
meningitis and provide education about signs and symp-
toms of meningitis. An ethically approved presentation 
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will describe the science behind the study, including 
information about IMD and the link between vaccination, 
carriage and herd protection. Communication material 
used in this study will be developed with input from focus 
groups run by two meningitis charities, Meningitis Now 
and the Meningitis Research Foundation, who will also 
coordinate the provision of ‘meningitis ambassadors’. 
Other initiatives include a social media policy engaging 
students, schools and research teams with curated social 
media posts to complement public engagement aims. 
Combining these strategies will ensure that participants 
make a fully informed decision to participate in the study. 
Furthermore, by involving entire school year cohorts 
(regardless of enrolment into the study), an estimated 
48 000 students across 200 schools will be engaged in a 
critical conversation about meningitis, research and the 
benefits of immunisation across the broader community. 
Study results will be submitted for publication in peer- 
reviewed journals, and then disseminated directly to the 
schools involved, as well as on the study social media plat-
forms, and the Meningitis Now and Meningitis Research 
Foundation websites.
Equality and diversity
The study will be done across 16 regions throughout 
the UK and will include schools across the range of 
Figure 3 Study design
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socioeconomic strata. School types reflect the variety of 
educational institutions across the UK as detailed in the 
study setting. Previous diversity information collected 
as part of UKMenCar4 across the same study network 
demonstrated that participants were reflective of their 
communities according to national census data.20 Inclu-
sion of whole schools, rather than targeting individuals, 
will encourage equal participation of diverse populations.
Sample handling and laboratory processes
Collected OPS will be placed immediately into STGG 
broth (skim milk, tryptone, glucose, glycerine; EO Labs, 
Bonnybridge, UK), maintained at 2°C–8°C until frozen at 
−80°C, within 4 hours of collection (figure 4). Site labo-
ratories will thaw and plate the OPS sample on selective 
GC- VCAT Agar (vancomycin, colistin amphotericin B, 
trimethoprim; Thermo Fisher Scientific, Basingstoke, 
UK) at 37°C in 5% CO2 for up to 48 hours. Putative Neis-
seria spp. (oxidase positive, Gram- negative diplococci) 
will be subcultured on to Columbia Horse Blood Agar, 
then stored in a bead- based cryovial (Technical Service 
Consultants, Lancashire, UK) at −80°C.
The Public Health England Meningococcal Reference 
Unit (Manchester) will serogroup putative Neisseria spp. 
isolates using an in- house dot- blot ELISA using National 
Institute for Biological Standards and Control monoclonal 
antibodies against capsular polysaccharide serogroups B, 
C, W and Y.26 DNA will be extracted using a bead- based 
MagMAX DNA Multi- Sample Ultra Kit (Thermo Fisher 
Scientific, Massachusetts, USA). Total DNA extracts will 
be normalised prior to whole genome sequencing on 
the Illumina NovaSeq6000 platform (Oxford Genomic 
Centre, Wellcome Trust Centre for Human Genetics, 
University of Oxford).
Genomes will be assembled using an in- house assembly 
pipeline (Department of Zoology, University of Oxford) 
which incorporates Velvet and VelvetOptimiser.27 28 Assem-
bled draft genome sequences will then be submitted to 
the open- access online database http:// pubMLST. org/ 
Figure 4 Laboratory analysis plan. CC clonal complex; cgMLST, core genome MLST; GC- VCAT, vancomycin, colistin, 
amphotericin B, trimethoprim; MLST, multilocus sequence typing; rMLST, ribosomal MLST; STGG; skim milk, tryptone, glucose, 
glycerine.
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neisseria, with isolate providence data and FASTQ files 
uploaded to the European Nucleotide Archive and the 
Sequence Read Archive Databases. Automated locus 
annotation using the BIGSdb software platform will be 
used concurrently with manual curation for classification 
of isolates including species, clonal complex, lineage, 
genogroup and meningococcal typing schemes for multi-
locus sequence typing (MLST), ribosomal MLST, core 
genome MLST and vaccine antigen variants (eg, Bexsero 
Antigen Sequence Type).29 30 After study completion, 
genomes will be published open access on the  pubMLST. 
org/ neisseria database and OPSs, Neisseria spp. isolates 
and any products of culture on GC- VCAT media will be 
stored in an approved facility for further research.
Potential benefits and harms
Participants will benefit from immunisation with a 
licensed ‘MenB’ vaccine which they would not other-
wise receive in the UK immunisation schedule. Prior to 
enrolment, participants will receive information about 
4CMenB and MenB- fHbp vaccination, according to the 
licensed product information. As a participant engage-
ment exercise, all participants completing the final 
swabbing visit will be entered into a prize- draw for head-
phones. Participants will not receive payments.
Safety reporting and study oversight
This study involves products used according to their 
licences. Safety monitoring will focus on detecting any 
serious adverse events (SAEs) and suspected unexpected 
serious adverse reactions (SUSARs). Specific SAE exemp-
tions include traumatic injuries, hospital admissions for 
intoxication, deliberate self- harm or elective manage-
ment of pre- existing conditions unless in response to 
a worsening of that condition since study enrolment. 
All SAEs will be reported to the chief investigator and 
to the sponsor, the University of Oxford Clinical Trials 
and Research Group. The Oxford University Hospitals 
National Health Service Foundation Trust/University of 
Oxford Trials Safety Group will review all new SAEs on 
a quarterly basis. SUSARs will be reported by the study 
chief investigator to the relevant competent authority 
and to the Research Ethics Committee. The lead site is 
the Oxford Vaccine Group, Department of Paediatrics, 
University of Oxford. The Scientific Advisory Board will 
provide input into study design, statistical analysis and will 
oversee safety reporting and study conduct in accordance 
with Good Clinical Practice. The Oxford Vaccine Group 
on behalf of the sponsor will act as the study monitor.
Statistical methods
A baseline analysis will occur after wave 2 when the study 
reaches approximately 50% enrolment. This descriptive 
analysis of baseline carriage rates will assess the validity 
of the prospective sample size calculation. There will 
be no interim analysis of vaccine impact. The principal 
analysis will be conducted using a modified intention to 
treat approach, including all participants who have had 
two throat swabs. Participants will be analysed according 
to allocated group, regardless of vaccine receipt. Based 
on previous UK school- based meningococcal carriage 
studies, the design effect was assumed to be 1.5 in the 
sample size calculations but will be calculated on the 
actual data collected.24 25
For the primary objective and each of the secondary 
objectives, carriage rates will be expressed as a mean 
with two- sided 95% Clopper- Pearson CIs for each group 
at baseline and at 12 months. The carriage rates in the 
MenB- fHbp and 4CMenB groups will be compared sepa-
rately to the Control Group. The OR with two- sided 95% 
CIs will be calculated using logistic regression via a gener-
alised estimating equations model using an exchange-
able working correlation structure. Model covariates will 
include age, gender, season of recruitment and baseline 
carriage status a priori. Additional risk factors found to 
affect carriage at baseline will also be included. Gender 
and smoking (smoking, home smoking and vaping) are 
known to affect both vaccine- induced immune responses 
and meningococcal carriage, and these interactions will 
be reported regardless of significance. The level of statis-
tical significance will be 0.05. There will be no imputation 
of missing data for the principal analysis.
Sensitivity analyses will be done for the primary and 
each of the secondary objectives and will include: anal-
yses without adjustment or inclusion of covariates for 
completeness and to confirm the results from the primary 
analyses; a per- protocol analysis of participants who 
received both vaccine doses in the 4CMenB and MenB- 
fHbp groups; adjustment for the month of the outcome 
measure rather than season of recruitment to further 
investigate the potential effect of seasonality and multi-
variable imputation for missing data. All variables that 
will be included in the analysis model will be included in 
the imputation model and will assume data are missing 
at random.
Data collection and management
Informed consent forms will be completed on paper. 
Source data entry will be on a standard case report form, 
either paper based, or direct electronic entry using 
REDCap, a browser- based electronic data capture record, 
hosted by the University of Oxford.31 Participant data will 
be handled in accordance with Good Clinical Practice 
and the General Data Protection Act. Participants will 
consent to the storage of de- identified OPSs, isolates and 
questionnaire data. All identifiable data will be destroyed 
after the youngest participant in the trial turns 21 years.
DISCUSSION
This is the first large- scale adolescent meningococcal 
carriage study to assess the impact of both the 4CMenB 
and MenB- fHbp vaccines on carriage of pathogenic 
meningococci as well as commensal Neisseria spp. Building 
on an established meningococcal carriage and vaccine 
clinical trial network, the backward compatibility of this 
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study will allow comparisons with four previous carriage 
studies in 1999, 2000, 2001 and 2014–2015. This study will 
also facilitate an evaluation of the UK adolescent quad-
rivalent MenACWY vaccination programme on carriage 
since its introduction in 2015. The 16 sites across the UK 
represent a geographically and demographically diverse 
population, increasing applicability to broad settings.
The ‘B Part of It’ trial showed that there is no signif-
icant difference in carriage of genogroup A, B, C, W, Y 
and X meningococci between adolescents who received 
4CMenB compared with controls.11 Overall, the carriage 
of genogroup B meningococcus was low. The ‘B Part of 
It’ Study has a similar design as a school- based study of 
adolescents aged 16–18 years; however, there are some 
notable difference between the design of the ‘B Part of 
It’ Study and the present study, specifically, the ‘Be on the 
TEAM’ Study:
1. Includes both MenB- fHbp and 4CMenB.
2. Allocates vaccine arms on a regional basis rather than 
cluster randomisation at the level of schools, which 
may increase the potential to observe herd protection.
3. Uses a 0- month and 6- month vaccine schedule, longer 
than the 1–2 month interval used in the ‘B Part of It’ 
Study.
4. Has a culture- defined endpoint of carriage, compared 
with direct PCR amplification targeting PorA in the ‘B 
Part of It’ Study.
Despite the difference in study designs, cross- study 
collaborations will enrich understanding of the poten-
tial vaccine impact on specific N. meningitidis strains and 
commensal Neisseria spp. by genome level interrogation.
The short follow- up period of between 6 and 9 months 
following the second vaccination is a limitation of this 
study, reducing the ability to observe any potential impact 
during later periods of high- acquisition risk, for example, 
when commencing tertiary education.32 The large sample 
size required and mobility of school- leavers limit the feasi-
bility of ongoing carriage surveillance. The secondary 
endpoint assessing the impact on other Neisseria spp. is 
based on those present in the oropharynx and culturable 
on selective media, however all swabs and products of 
culture will be stored for potential further analysis.
Due for completion in 2021, The ‘Be on the TEAM’ 
Study will directly inform international MenB immuni-
sation policy. It will contribute to an open- access repos-
itory of Neisseria spp. genomes and provide a biobank of 
samples to assist in identifying strategies for future MenB 
vaccine development.
Current study progress
At the time of writing 24 048 participants have been 
enrolled from over 120 schools across the UK. Assemblies 
raising awareness about meningitis, immunisation and 
research have reached over 40 000 students. In March 
2020, study visits were temporarily suspended due to the 
SARS- CoV-2 pandemic and at this time, 11 170 partici-
pants had successfully completed the study. The protocol 
may require modifications to fulfil the study objectives.
Protocol version
Current Protocol Version 5.0 dated 24- Jan-2020. All 
protocol modifications will be reported promptly to the 
NIHR, Department of Health and Human Services, the 
Scientific Advisory Board and the Principal Investiga-
tors. This report was written using the SPIRIT checklist.33 
The study protocol, patient information sheets and an 
example consent form are publicly available on the study 
website: www. beontheteam. uk.
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